Biopharmaceutical firm Berg has begun a Phase I/II monotherapy clinical trial of its drug candidate BPM 31510-IV to treat patients with glioblastoma multiforme (GBM).
The open-label, non-randomised Phase I/II trial will evaluate the safety and tolerability of the drug in patients with glioblastoma multiforme that has recurred on a bevacizumab-containing regimen.
The trial is being conducted at the Stanford University School of Medicine and is designed to further determine secondary outcome measures such as BPM31510-IV's pharmacokinetics and pharmacodynamics.
Berg co-founder, president and chief executive officer Niven Narain said: "Glioblastoma is one of the deadliest and most insidious forms of cancer and we are working to make a much-needed difference in the lives of patients with glioblastoma to improve survival and quality of life.
"The initiation of this Phase I/II trial marks the continued advancement of BPM 31510-IV, and further demonstrates BERG's Interrogative Biology platform."
BPM 31510-IV is developed to reverse the compromised metabolism of cancer cells by slowing or stopping the growth of these cells.
Results from a Phase I clinical trial of the drug to treat solid tumours showed its safety, while the preclinical studies indicated therapeutic efficacy of the drug as a single agent in GBM.
The firm further studied the drug in combination with temozolamide (TMZ) in preclinical models, and found that this combination therapy decreased the cancer cell proliferation when compared to monotherapy.
The firm has also initiated a Phase II trial in advanced pancreatic cancer in combination with a common cancer drug.